A+ a-
Stay Connected Research News Discussion Forum Advocacy and Support Organizations Patient Meeting Calendar Movement Disorder Glossary Movement Disorders Virtual University Linkage Library
WE MOVE

Make a Donation
Ataxia
Bradykinesia
Choreoathetosis
Corticobasal Degeneration
Dyskinesias (Paroxysmal)
Dystonia
Essential Tremor
Hereditary Spastic Paraplegia
Huntington's Disease
Multiple System Atrophy
Myoclonus
Parkinson's Disease
Progressive Supranuclear Palsy
Restless Legs Syndrome
Rett Syndrome
Spasticity
Sydenham's Chorea
Tardive Dyskinesia
Tics
Tourette's Syndrome
Tremor
Wilson Disease
 

Botulinum Toxin Type B for Dystonia

On December 11, 2000, a botulinum toxin type B product (Myobloc™) was approved by the FDA in the United States as a treatment for patients with cervical dystonia. Myobloc™ is the U.S. trade name for Solstice Neurosciences' botulinum toxin type B product. This product also received marketing authorization from the European Union's Committee for Proprietary Medicinal Products and is available there as Neurobloc®.

Safety and efficacy were demonstrated in double-blind clinical trials in patients who had responded to BoNT-A and in patients who had developed resistance to BoNT-A. BoNT-A and BoNT-B have slightly different chemical structures and their primary mechanisms of action on acetylcholine also differ.

Please refer to E-MOVE Article: BoNT-B for cervical dystonia (AAN report)
Please see: Toxins '99 Meeting Reports